The Technology Centre of New Jersey
675 U.S. Route One, South
About Advaxis, Inc.Advaxis is a clinical-stage biotechnology company developing cancer immunotherapies that enlist the body’s own immune system to fight cancer.
CEO: Daniel O’Connor
CFO: Sara Bonstein
CSO (Scientific): Robert Petit
Please click here for Advaxis job opportunities.
Please click here for clinical trial information.
Tweets by Advaxis
496 articles with Advaxis, Inc.
Advaxis, Inc. will present a corporate overview at the 11th Annual LD Micro Main Event on Tuesday, December 4, 2018 at 5:00 p.m. (Pacific). The conference will be held on December 4-6, 2018 at the Luxe Sunset Bel-Air, California.
Advaxis to Present Poster Entitled “Natural Killer (NK) Cells Orchestrate the Antitumor Activities of Listeria monocytogenes (Lm)-Based Immunotherapy” at Society for Immunotherapy of Cancer Annual Meeting
Results Show Treatment of Tumor-Bearing Mice with Axalimogene Filolisbac (AXAL) Leads to Natural Killer Cell Activation and Other Important Immune-Related Effects
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that it will be continuing its ongoing Phase 3, randomized, double-blinded, placebo-controlled, pivotal study of axalimogene filolisbac
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will host a business update call on Friday, November 2, 2018.
Common stock and warrants were sold together in fixed combination at $1.20 per unit, totaling approximately $20 million in gross proceeds
Advaxis, Inc. announced today that it intends to offer and sell in an underwritten public offering shares of its common stock, with each share of common stock to be sold together in a fixed combination with a warrant to purchase common stock.
Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer
July 30, 2018 12:00 UTC Advaxis Announces FDA Allowance of IND Application for ADXS-HOT Drug Candidate for Non-Small Cell Lung Cancer Selects Bladder Cancer as Third ADXS-HOT Drug Candidate to Take into the Clinic after Non-Small Cell Lung and Prostate Cancers Advances Goal to Have Five Neoantigen-Based Drug Candidates in Clinical Evaluation by 4Q 2019 PRINCETON, N.J.--( BUSINESS WIRE )-- Advaxis,
Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab
Advaxis, Inc. announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Company’s Investigational New Drug (IND) application for its Phase 1/2 study of axalimogene filolisbac (AXAL)
Shares of Advaxis are skyrocketing this morning after the company announced the U.S. Food and Drug Administration lifted the clinical hold on its Investigational New Drug Application for a Phase I/II cancer study.
Advaxis, Inc. announced a clinical update
Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens
Advaxis, Inc., announced it has commenced a Phase 1 trial with the dosing of the first patient with ADXS-NEO, an investigational personalized immunotherapy approach targeting personal neoantigens found by sequencing a patient’s own cancer cells.
Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results
Advaxis, Inc. today announced a new prioritization of its product portfolio, as well as financial results and business highlights for the three months ended April 30, 2018.
Effective June 6, 2018.
Findings will be highlighted in a poster discussion at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting underway in Chicago, on Saturday, June 2, from 4:45 pm to 6:00 p.m. CDT
Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018
Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take place on Thursday, June 7, 2018.
Preclinical findings were discussed in poster presentations at the recent American Association for Cancer Research (AACR) Annual Meeting.
4/23/2018After nearly a year without a permanent chief executive officer Advaxis, Inc. has a new hand on the wheel. This morning the company announced Kenneth A. Berlin will take over the helm of the company as president and CEO effective immediately.
Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting
Lm platform targets common mutations in tumor driver genes.
Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting
The discussion will be presented and lead by author and principle investigator of the study, Mark Stein, MD, medical oncologist at Columbia University Medical Center.
The FDA placed a hold on Advaxis' Phase I/II trial following the death of a patient.